Immunotherapy Advancements in Cancer Treatment

Year : 2024 | Volume : | : | Page : –
By

Divyashree Patil,

Divyani Patil,

Bhagyashri Patil,

Amitkumar Dhankani,

Mansi Dhankani,

Sunil Pawar,

  1. Student, Dept of Quality assurance, Poojya Sane Guruji Vidya Prasarak Mandal’s College of Pharmacy, Maharashtra, India
  2. Student, Dept of Quality assurance, Poojya Sane Guruji Vidya Prasarak Mandal’s College of Pharmacy, Maharashtra, India
  3. Student, Dept of Quality assurance, Poojya Sane Guruji Vidya Prasarak Mandal’s College of Pharmacy, Maharashtra, India
  4. Assistant Professor, Dept of Quality assurance, Poojya Sane Guruji Vidya Prasarak Mandal’s College of Pharmacy, Maharashtra, India
  5. Assistant Professor, Dept of Quality assurance, Poojya Sane Guruji Vidya Prasarak Mandal’s College of Pharmacy, Maharashtra, India
  6. Principal, Poojya Sane Guruji Vidya Prasarak Mandal’s College of Pharmacy, Maharashtra, India

Abstract

‘]

Immuno-oncology has been one of the more exciting developments in the field of cancer treatment since about a century ago, with William B. Coley’s work in the late 19th century, which really gave the field its beginnings with “Coley’s toxin.” In an initial effort that proved unsuccessful, early immunotherapy approaches utilizing bacterial mixtures to induce immune responses against tumors nonetheless laid some groundwork for this field. It wasn’t until over a century later that the first discoveries of immune checkpoint inhibitors like CTLA-4 and PD-1 changed things. Such therapies increase immune responses against cancer cells by circumventing mechanisms that suppress immune activity. Another approach that is just coming into maturity includes CAR-T cell therapy, monoclonal antibodies, cytokines, and therapeutic vaccines, among many others, for exploiting the body’s immune system in cancer therapy. Notwithstanding these developments, challenges persist in optimizing the delivery mechanisms and overcoming tumor immunosuppression in solid tumors. Against this backdrop, this abstract reflects on the evolution, mechanisms, and current challenges of immunotherapy in cancer treatment, underscoring its potential to be transformative and requiring continuous effort to enhance its efficacy and safety.

Keywords: Immuno-oncology, Coley’s toxin, Immune checkpoint inhibitors, CTLA-4, PD-1

How to cite this article:
Divyashree Patil, Divyani Patil, Bhagyashri Patil, Amitkumar Dhankani, Mansi Dhankani, Sunil Pawar. Immunotherapy Advancements in Cancer Treatment. Research & Reviews: A Journal of Pharmacology. 2024; ():-.
How to cite this URL:
Divyashree Patil, Divyani Patil, Bhagyashri Patil, Amitkumar Dhankani, Mansi Dhankani, Sunil Pawar. Immunotherapy Advancements in Cancer Treatment. Research & Reviews: A Journal of Pharmacology. 2024; ():-. Available from: https://journals.stmjournals.com/rrjop/article=2024/view=175473



Fetching IP address…

References ‘]

  1. Esfahani, K et al. “A review of cancer immunotherapy: from the past, to the present, to the future.” Current oncology (Toronto, Ont.) 27,Suppl 2 (2020): S87-S97. doi:10.3747/co.27.5223
  2. Shiravand, Yavar et al. “Immune Checkpoint Inhibitors in Cancer Therapy.” Current oncology (Toronto, Ont.) 29,5 3044-3060. 24 Apr. 2022, doi:10.3390/curroncol29050247
  3. Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. The identification of immunological biomarkers in kidney cancers. Frontiers in Oncology. 2018 Nov 2;8:456.
  4. Sterner, R.C., Sterner, R.M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J.11, (4)69 (2021). https://doi.org/10.1038/s41408-021-00459-7
  5. Immunotherapy for Cancer [Internet]. Cancer.gov. Cancer.gov; 2019 [cited 2024 Sep 13]. Available from: ‌https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
  6. Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduction and Targeted Therapy. 2023 Dec 13;8(1):450.
  7. Rosenberg, Steven A et al. “Adoptive cell transfer: a clinical path to effective cancer immunotherapy.” Nature reviews. Cancer 8,4 (2008): 299-308. doi:10.1038/nrc2355
  8. CAR T-Cell Development Services [Internet]. Bpsbioscience.com. 2024 [cited 2024 Sep 12]. Available from: ‌ https://bpsbioscience.com/custom-car-t-cell-development
  9. Muthukutty, Palaniyandi et al. “Recent Advances in Cancer Immunotherapy Delivery Modalities.” Pharmaceutics 15,2 504. 2 Feb. 2023, doi:10.3390/pharmaceutics15020504
  10. Liu X, Cheng Y, Liu Y, Hu X, Wen T. Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview. Frontiers in Immunology. 2024 Jan 17;15:1328145.
  11. Ding Y, Wang Y, Hu Q. Recent advances in overcoming barriers to cell‐based delivery systems for cancer immunotherapy. InExploration 2022 Jun (Vol. 2, No. 3, p. 20210106).
  12. Yang M, Olaoba OT, Zhang C, Kimchi ET, Staveley-O’Carroll KF, Li G. Cancer immunotherapy and delivery system: an update. Pharmaceutics. 2022 Aug 4;14(8):1630.
  13. Pérez-Herrero E, Lanier OL, Krishnan N, D’Andrea A, Peppas NA. Drug delivery methods for cancer immunotherapy. Drug Delivery and Translational Research. 2024 Jan;14(1):30-61.
  14. Fan X, Wang K, Lu Q, Lu Y, Sun J. Cell‐based drug delivery systems participate in the cancer immunity cycle for improved cancer immunotherapy. Small. 2023 Jan;19(4):2205166.

 

Ahead of Print Subscription Review Article
Volume
Received August 3, 2024
Accepted September 14, 2024
Published September 26, 2024
Views: 154

Check Our other Platform for Workshops in the field of AI, Biotechnology & Nanotechnology.
Learn more
Check Out Platform for Webinars in the field of AI, Biotech. & Nanotech.
Learn more